BGU substance abuse expert wins U.S. National Distinguished International Scientist Award

NewsGuard 100/100 Score

Prof. Richard Isralowitz, of Israel's Ben-Gurion University of the Negev (BGU), recently received the U.S. National Distinguished International Scientist Award for his work as director of the Regional Alcohol and Drug Abuse Resources (RADAR) Center.

This award is presented by the International Program of the National Institute on Drug Abuse (NIDA), which works with colleagues from around the world to find evidence-based solutions to the public health problems of drug abuse, addiction and drug-related HIV/AIDS.

Established in 1995, RADAR's research focuses on substance use and related problems among Israeli and former Soviet Union-origin youth and adults. The Center is part of an international network of experts and organizations addressing substance abuse prevention, treatment and policy issues through education, training workshops, research, and publications.

RADAR has sponsored five international substance abuse experts at BGU for research and training purposes under the Fulbright Scholar Exchange Program - U.S.-Israel Educational Program. It is monitoring substance use in the Middle East, improving clinical treatment needs of addicted persons, and developing an evidence-based model of smoking cessation among high-risk youth in the Negev.

"Social outreach to communities in the Negev is a major component of BGU's mission," said Doron Krakow, executive vice president of American Associates, Ben-Gurion University of the Negev based in New York City. "I congratulate Prof. Isralowitz on this well-deserved honor and for his critical efforts on behalf of underserved populations."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis